Awaiting development: Guidance and quality standards

Showing 301 to 310 of 359

Guidance and quality standards awaiting development
Title	Type
Tanruprubart for treating Guillain–Barre syndrome in people 12 years and over	Technology appraisal guidance
Tarlatamab for maintenance treatment of extensive-stage small-cell lung cancer [ID6749]	Technology appraisal guidance
Tarlatamab for treating limited-stage small-cell lung cancer after chemoradiotherapy [ID6748]	Technology appraisal guidance
Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191]	Technology appraisal guidance
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]	Technology appraisal guidance
Teplizumab for delaying progression of stage 3 type 1 diabetes in people 8 years and over [TSID12403]	Technology appraisal guidance
Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915]	Technology appraisal guidance
Tildrakizumab for treating active psoriatic arthritis [ID6724]	Technology appraisal guidance
Timrepigene emparvovec for treating choroideremia [ID3916]	Technology appraisal guidance
Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064]	Technology appraisal guidance